Evolus Q1 revenue rises 7% on product sales

ReutersMay 4, 2026 8:24 PM

View all comments（0）



Overview

US performance beauty firm's Q1 revenue rose 7% yr/yr, driven by Jeuveau and HA gel sales
Company posted second straight quarter of positive adjusted EBITDA, reflecting improved operating leverage
Evolus reaffirmed full-year 2026 guidance for double-digit revenue growth and positive adjusted EBITDA margin

Outlook

Evolus projects 2026 net revenue between $327 mln and $337 mln
Company expects 2026 adjusted gross profit margin of 65.5% to 67.0%
Evolus anticipates low- to mid-single digit adjusted EBITDA margin in 2026

Result Drivers

JEUVEAU DEMAND - Co said unit growth for Jeuveau across U.S. and international markets supported Q1 revenue
HA GEL CONTRIBUTION - Injectable hyaluronic acid gels contributed to expanding share of wallet and Q1 revenue
CUSTOMER ENGAGEMENT - Increased customer penetration, strong reorder behavior, and loyalty program expansion drove results

Company press release: ID:nBw5Shkp1a

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Product Revenue		$72.75 mln
Q1 Net Income		-$10.67 mln
Q1 Gross Margin		66.90%
Q1 Adjusted Gross Margin		68.00%
Q1 Gross Profit		$48.90 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Evolus Inc is $14.00, about 162.7% above its May 1 closing price of $5.33

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Trump’s China Visit Boosts China Stocks Nearly 4%, Alibaba Favored by AI Bets Despite Weak Results

TradingKey - On May 13 (ET), U.S. President Trump arrived in Beijing to begin a three-day visit. Markets expect both sides to engage in dialogue on issues such as trade and technology, a move that has eased concerns over a further escalation of U.S.-China tensions.

Pricing Hiked Three Times to $185. What Gives Cerebras Confidence in Its $49B Valuation After Spurning SoftBank?

TradingKey - AI chipmaker Cerebras Systems is racing toward a US IPO with momentum far exceeding expectations, as Wall Street's fervor for the AI semiconductor sector is fully reflected in the company.

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools